Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 4/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | APP | P05067 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3188765 | 0.98 | HDAC4 (0.48) | HDAC4P2RX7ALDH1A1HSD11B1AKR1C1 | |
| SCHEMBL2790870 | 0.92 | HDAC3 (0.44) | HDAC4P2RX7ALDH1A1HSD11B1AKR1C1 | |
| SCHEMBL4811086 | 0.88 | HDAC4 (0.47) | HDAC4P2RX7ALDH1A1HSD11B1HDAC3 | |
| SCHEMBL16220556 | 0.84 | HDAC4 (0.50) | HDAC4P2RX7ALDH1A1HSD11B1HDAC3 | |
| SCHEMBL9480750 | 0.82 | SLC6A4 (0.49) | HDAC4P2RX7ALDH1A1HSD11B1AKR1C1 | |
| SCHEMBL18742410 | 0.81 | P2RX7 (0.44) | HDAC4P2RX7ALDH1A1HSD11B1HDAC3 | |
| SCHEMBL2246610 | 0.79 | PDE5A (0.42) | HDAC4ALDH1A1AKR1C1SMN1; SMN2CYP2C19 | |
| SCHEMBL1345655 | 0.76 | HDAC4 (0.48) | HDAC4ALDH1A1HSD11B1AKR1C1HDAC3 | |
| SCHEMBL28296820 | 0.76 | PSEN1 (0.49) | HDAC4AKR1C1PSEN1PSEN2APH1B | |
| SCHEMBL150588 | 0.75 | ALDH1A1 (0.47) | P2RX7ALDH1A1AKR1C1SMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835475-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8501794-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2344463-A2 | 1,2 -THIAZOL YL DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110082116-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-04-07 | — | — | US | disclosed |
| US-7872033-B2 | N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100234345-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-09-16 | — | — | US | disclosed |
| WO-2010054024-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-05-14 | — | — | WO | disclosed |
| EP-2146973-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2010-01-27 | — | — | EP | disclosed |
| US-20090023789-A1 | N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | US | disclosed |
| US-7465719-B2 | Carbamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2008-12-16 | — | — | US | disclosed |
| US-20060058282-A1 | Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors | TOPOTARGET UK LIMITED (GB) | 2006-03-16 | — | — | US | disclosed |
| US-20060041139-A9 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | H. LUNDBECK A/S (DK) | 2006-02-23 | — | — | US | disclosed |
| EP-1590326-A2 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | H. Lundbeck A/S (DK) | 2005-11-02 | — | — | EP | disclosed |
| EP-1583736-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN ESTER OR KETONE LINKAGE AS HDAC INHIBITORS | TopoTarget UK Limited (GB) | 2005-10-12 | — | — | EP | disclosed |
| US-20040186103-A1 | Substituted alkyl amido piperidines | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-09-23 | — | — | US | disclosed |
| WO-2004065354-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN ESTER OR KETONE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004064764-A2 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | H. LUNDBECK A/S (DK) | 2004-08-05 | — | — | WO | disclosed |
| US-20040073036-A1 | Substituted alkyl amido piperidines | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-15 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023789-A1 | N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | CNR2, CNR1, TBXA2R | HDAC4 1409/4885P2RX7 64/4885ALDH1A1 1737/4885 |
| US-20060058282-A1 | Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors | HDAC1, HDAC7, HDAC11 | HDAC4 9/4885P2RX7 4166/4885ALDH1A1 1211/4885 |
| US-20040073036-A1 | Substituted alkyl amido piperidines | MCHR1, MCHR2, MC1R | HDAC4 2120/4885P2RX7 517/4885ALDH1A1 604/4885 |
| US-20110082116-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | HDAC4 1608/4885P2RX7 358/4885ALDH1A1 1465/4885 |
| US-20100234345-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | HDAC4 1640/4885P2RX7 351/4885ALDH1A1 1518/4885 |
| US-20060041139-A9 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | MCHR1, MCHR2, MC1R | HDAC4 2120/4885P2RX7 517/4885ALDH1A1 604/4885 |
| US-20040186103-A1 | Substituted alkyl amido piperidines | MCHR1, MCHR2, MC1R | HDAC4 2120/4885P2RX7 517/4885ALDH1A1 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.